SMS

SMS Lifetime Achievement Award

This award is intended to honor the highest level of achievement in Strategic Management by a business leader.  It is not an annual award; it is only given when an appropriate honoree is available.  The honoree receives a suitable plaque and has the “citation of accomplishment” published in the Strategic Management Journal. In addition the honoree is invited to give a lecture at the SMS Annual International Conference, which is subsequently published in the Strategic Management Journal.

Award Criteria

  • The honoree must have demonstrated sustained strategic leadership and innovation that significantly altered strategy practice.  In this regard, “sustained” means across business cycles.  It is hard to envision this period being shorter than a decade.
  • Furthermore, this leadership and innovation must be such that it significantly impacts strategy practice in industries beyond the home industry of the honoree, and is the subject of academic attention in major business schools.
  • The honoree should be in the later stages of his/her career or be recently retired.  Generally this would mean someone over 55 years of age, although occasional exceptions may occur.

The SMS Lifetime Achievement Award Committee is composed of the Executive Committee of the SMS Board of Directors.

2017 Lifetime Achievement Award Recipient: John Mendelsohn, MD

Dr. John Mendelsohn served as president of The University of Texas M.D. Anderson Cancer Center from 1996 to 2011 during a period of tremendous growth in clinical and research activities, and continues as Director of the institution’s Sheikh Khalifa Institute for Personalized Cancer Therapy.  He is a senior fellow in health and technology at the James A. Baker III Institute for Public Policy at Rice University and is founding chair of the Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine.    At the University of California, San Diego from 1970 to 1985, he was the founding director of its cancer center.  At Memorial Sloan-Kettering Cancer Center from 1985 to 1996 he chaired the Department of Medicine and co-headed Molecular Pharmacology and Therapeutics. Dr. Mendelsohn’s laboratory research from 1970-1996 pioneered the now universally adopted concept of targeted anti-receptor therapy that blocks key molecular signaling pathways in cells, as a new form of cancer treatment.  He has authored more than 250 scientific papers, reviews and book chapters, has received many honors and awards, was elected to the National Academy of Medicine and the American Academy of Arts and Sciences, and recently served as chairman of the Houston Grand Opera.

The SMS will present the Lifetime Achievement Award to Dr. Mendelsohn at the 37th Annual SMS  Conference in Houston on  Monday, October 30th.